Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic LifePak DTC Ads May Foreshadow Future Heart Failure Campaign

This article was originally published in The Gray Sheet

Executive Summary

Medtronic says it will evaluate its LifePak Home Solution automated external defibrillator direct-to-consumer advertising campaign with an eye toward similar promotional efforts for other therapies, such as resynchronization for congestive heart failure

You may also be interested in...



Philips’ HeartStart Defibrillator Seeks To Make Itself At Home In AED Market

Philips Electronics' HeartStart home defibrillatorwill reach select CVS pharmacies in January 2003; the prescription-use device will list for $2,295

Philips’ HeartStart Defibrillator Seeks To Make Itself At Home In AED Market

Philips Electronics' HeartStart home defibrillatorwill reach select CVS pharmacies in January 2003; the prescription-use device will list for $2,295

FDLI In Brief

OPPS: Proposed rule for the hospital outpatient prospective payment system, including information on new device categories, will be issued "around the fourth of July," CMS Purchasing Policy Group Director Thomas Gustafson tells attendees at the Food and Drug Law Institute's annual meeting held in Washington, D.C. April 16-17. A final rule is on schedule for promulgation by Oct. 1. According to Gustafson, 83 out of 97 device categories are scheduled to sunset and lose their "pass-through" status in January 2003...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel